US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

41.03 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish ↗
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock 
Via MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum ↗
Via Chartmill
Apellis Pharmaceuticals (NASDAQ:APLS): Strong Growth Stock with a Technical Breakout Setup ↗
Via Chartmill
News headline image
Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Why Biogen Stock Was a Winner on Wednesday ↗
The biotech's growth portfolio continues to add to its overall top line. 
Via The Motley Fool
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS): A Fitting GARP Opportunity ↗
Via Chartmill
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Emerges as a Growth Stock with Bullish Technical Breakout Potential ↗
Via Chartmill
Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate ↗
Via Chartmill
News headline image
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
Why Biogen Stock Got Mashed on Monday ↗
Its first-quarter expenses will be notably higher than anticipated. 
Via The Motley Fool
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis... 
Via MarketMinute
News headline image
The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge
As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive... 
Via MarketMinute
News headline image
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti
Via Business Wire
News headline image
Why Biogen Stock Sank While the Market Soared on Thursday ↗
It's reaching into its coffers for a $5.6 billion acquisition. 
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to... 
Via MarketMinute
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
Via AB Newswire
These stocks are making the most noise in today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >